COPD Clinical Trials in North Carolina

23 recruiting studies across 2 cities

Browse by City

All Trials in North Carolina

Phase

Trial	Phase	Sponsor	Dist.
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD	Phase 2	Verona Pharma plc	<1 mi
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	Hoffmann-La Roche	<1 mi
A Study to Evaluate Solrikitug in Participants With COPD (ZION)	Phase 2	Uniquity One (UNI)	<1 mi
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)	Phase 3	AstraZeneca	<1 mi
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.	Phase 4	Sanofi	<1 mi
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD	Phase 2	Upstream Bio Inc.	<1 mi
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease	Phase 3	AstraZeneca	<1 mi
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening	—	Freenome Holdings Inc.	<1 mi
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease	Phase 3	Hoffmann-La Roche	13 mi
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)	Phase 2	Connect Biopharm LLC	21 mi
Pulmonary Hypertension SOLAR	Phase 2	Bastiaan Driehuys	21 mi
Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia	Phase 2	Bastiaan Driehuys	21 mi
Photon-counting CT in Chest Imaging	N/A	Duke University	21 mi
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD	Phase 2	Johns Hopkins University	21 mi
STRIVE Post-Market Registry Study	—	Olympus Corporation of the Americas	21 mi
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)	Phase 3	AstraZeneca	23 mi
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)	Phase 3	GlaxoSmithKline	23 mi
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease	Phase 1	GlaxoSmithKline	23 mi
Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)	Early 1	University of North Carolina, Chapel Hill	25 mi
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease	Phase 1	Genentech, Inc.	25 mi
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease	Phase 2	AstraZeneca	35 mi
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype	Phase 3	Sanofi	39 mi
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype	Phase 3	Sanofi	45 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.